MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Byoung Chul Cho, Alexander I. Spira, Benjamin Besse et al.|Future Oncology|2021

Cited by 93